Influence of Chlorthalidone on the Pharmacokinetics and Pharmacodynamics of Org 10172 (Lomoparan®), A Low Molecular Weight Heparinoid, in Healthy Volunteers
- 1 July 1991
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 31 (7) , 611-617
- https://doi.org/10.1002/j.1552-4604.1991.tb03746.x
Abstract
The influence of chlorthalidone (100 mg po) on the pharmacokinetics and pharmacodynamics of Org 10172 (IV bolus injection of 3250 anti‐Xa units), a low molecular weight heparinoid, was studied in six healthy male volunteers using an open randomized two‐way crossover design. Chlorthalidone produced a slight decrease in clearance of anti‐Xa activity from 7.1 ± 1.0 to 6.6 ± 0.8 mL/min and a decrease of the volume of distribution from 0.20 ± 0.05 to 0.16 ± 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 ± 0.05 to 0.26 ± 0.10 L/kg (all differences P <.05). During the entire study period no adverse events occurred. In summary, chlorthalidone showed separate effects on different fractions of Org 10172. The clinical implication of the slight change observed in plasma anti‐Xa activity is likely to be limited, whereas the 80% increase in distribution volume of plasma antithromhin activity can not be defined as yet in terms of clinical relevance.Keywords
This publication has 11 references indexed in Scilit:
- Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.British Journal of Clinical Pharmacology, 1989
- Anticoagulantly Active Heparan Sulfate Proteoglycan and the Vascular EndotheliumSeminars in Thrombosis and Hemostasis, 1987
- Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathwaysBlood, 1984
- Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic diseaseAnnals of Neurology, 1984
- ELSMOS — an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementationComputer Programs in Biomedicine, 1984
- USE OF A NEW HEPARINOID AS ANTICOAGULANT DURING ACUTE HAEMODIALYSIS OF PATIENTS WITH BLEEDING COMPLICATIONSThe Lancet, 1983
- A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal modelsThrombosis Research, 1982
- Absolute bioavailability of chlorthalidone in man: A cross-over study after intravenous and oral administrationEuropean Journal of Clinical Pharmacology, 1979
- Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238)Thrombosis Research, 1978
- Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin IIIThrombosis Research, 1977